Neurotrophic Keratitis: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate®) Submitted by Dompé
MILAN--(BUSINESS WIRE)--The biopharmaceutical company Dompé announced the acceptance of the registration application submitted to the European Medicines Agency (EMA) for Oxervate® eye drops, for the treatment of moderate and severe neurotrophic keratitis in adult patients. Acceptance by EMA constitutes the initiation of the dossier's scientific review procedure, in order to obtain authorisation to market the medicinal product, which was designated an orphan drug for the treatment of neurotrophi